Free Trial

Rohin Patel Analyst Performance

Analyst at JPMorgan Chase & Co.

Rohin Patel is a stock analyst at JPMorgan Chase & Co. in the medical sector, covering 2 publicly traded companies. Over the past year, Rohin Patel has issued 4 stock ratings, including buy and hold recommendations. While full access to Rohin Patel's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Rohin Patel's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
4 Last 0 Years
Buy Recommendations
50.00% 2 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy50.0%2 ratings
Hold50.0%2 ratings
Sell0.0%0 ratings

Out of 4 total stock ratings issued by Rohin Patel at JPMorgan Chase & Co., the majority (50.0%) have been Buy recommendations, followed by 50.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NYSE
50.0% of companies on NYSE
1 company
NASDAQ
50.0% of companies on NASDAQ
1 company

Rohin Patel, an analyst at JPMorgan Chase & Co., currently covers 2 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
100.0%

Rohin Patel of JPMorgan Chase & Co. specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED PRODUCTS
1 company
50.0%
MED INSTRUMENTS
1 company
50.0%

Rohin Patel's Ratings History at JPMorgan Chase & Co.

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Haemonetics Corporation stock logo
HAE
Haemonetics
12/12/2025Boost Price Target$82.65$74.00Neutral
NeuroPace, Inc. stock logo
NPCE
NeuroPace
12/10/2025Boost Price Target$16.47$20.00Overweight
NeuroPace, Inc. stock logo
NPCE
NeuroPace
11/5/2025Boost Price Target$12.95$18.00Overweight
Haemonetics Corporation stock logo
HAE
Haemonetics
8/8/2025Reiterated Rating$55.49$62.00Neutral